PROZ is correlated with sorafenib resistance and the number of CD8-positive T infiltrates that represent effective immunotherapy, providing a new potential therapeutic target to improve the efficacy of targeted immune combination therapy for advanced HCC. This evidence concerns the gene PROZ and hepatocellular carcinoma.